VBI Vaccines Total Revenue

VBI Vaccines (VBIV) currently reports a total revenue of $9.4M as of March 2024. That compares with $1.4M in the prior-year period — up 553.1% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore VBI Vaccines's total revenue history and peer comparisons.

VBI Vaccines's total revenue increased from $1.4M to $9.4M — a 553.1% year-over-year increase (period ending March 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

VBI Vaccines's total revenue of $9.4M is lower than the Healthcare sector average of $110B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

VBI Vaccines reported $9.4M in total revenue as of March 2024. That compares with $1.4M in the prior-year period — up 553.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total revenue of $9.4M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for VBI Vaccines, and consider following VBIV for alerts when major investors trade the stock.